Abstract: The purpose of this study is to investigate the potential impact of differing lung cancer risks in study populations on estimating population attributable fraction (PAF) from asbestos exposure. Studies were identified via a MEDLINE search up to September 2009 and from the reference lists of publications about asbestos exposure and lung cancer risk. Relative risk estimates were extracted from 160 studies and meta-relative risks were calculated according to randomeffect models. Hypothetical PAFs were calculated based on the meta results and on the difference exposure scenarios. The risks for lung cancer from asbestos exposure were variable according to the region as well as other study characteristics. The risk estimates proved higher in Asian countries (RR=3.53), in studies with 500 or fewer subjects (RR=2.26), and papers published in the 1990s or earlier (RR=1.91), than did those for European or North American countries, studies with more than 500 subjects, and papers published in the 2000s, respectively. The differences in PAFs between Asian and North American studies were 15.5%, 30.3%, and 36.2% when the exposure prevalence was 10%, 30%, and 50%, respectively. This study suggested that it is important to apply appropriate lung cancer estimates to each study population when calculating PAF from asbestos exposure.
Introduction
Population attributable fraction (PAF) is a useful index to quantify the burden of a given risk factor by combining relative risk with prevalence of exposure 1) . Although PAF primarily depends on prevalence of exposure, another important determinant is the disease risk of the study population. However, it has been assumed that in many circumstances the relative risk (RR) remains essentially constant between populations when in fact it may vary considerably across different countries and time periods. Asbestos ranks as one of the major occupational carcinogens and 5-7% of worldwide lung cancer cases may be attributable to occupational asbestos exposure 2) .
Previously, the most widely cited figures for calculating PAF from asbestos exposure are likely those published by *To whom correspondence should be addressed. Email: leewj@korea.ac.kr
©2013 National Institute of Occupational Safety and Health
Industrial Health 2013, 51, [128] [129] [130] [131] [132] [133] Original Article Goodman 3) , which are based on meta-analysis of cohort studies, as in French 4) and UK 5) studies. World Health
Organization used an estimate published by Steenland 6) to assess the burden of lung cancer from occupational exposure 7) . However, it is difficult to be certain that a summary relative risk collected through meta-analysis is relevant to other populations due to likely differences in working conditions, exposure levels, and ethnic characteristics. Similarly, it is uncertain whether modern relative risks are relevant to past conditions and whether data from specific worksites are relevant to those in all other countries. The aim of this study, therefore, is to produce updated estimates by different study characteristics of lung cancer risk due to asbestos exposure, and then to use these data to present potential differences for calculating PAF that will help to inform more appropriate future measures of lung cancer burden.
Materials and Methods

Calculation of relative risk estimates
The following medical subject headings and key words were used for searching out studies investigating the relation of asbestos exposure to lung cancer mortality or incidence: asbestos, lung, neoplasms, and risk. Original data for inclusion were identified through a MEDLINE search of literature published up to September 2009, without limitations on study period or language. In addition, the references in individual studies and reviews were similarly searched for further studies not obtained through the literature search. Through this process, a total of 7,394 studies were identified.
All titles and abstracts identified were screened and exclusion criteria were applied to the complete articles. Our exclusion criteria were: (a) not original research, not human study, (c) case reports and case series, (d) clinical lung cancer outcomes (e.g., diagnostic or therapeutic studies of lung cancer). Among the total, 7,088 studies were excluded and the remaining 306 studies were then reviewed in detail. By means of the detailed review of these articles, we also excluded (a) studies lacking an estimated risk outcome (e.g., RR, OR, SMR, SIR and 95% CI) or sufficient data for calculation of the estimates, studies carried out on multiple exposures such as exposure to asbestos and other carcinogens, and (c) duplicated studies. When multiple studies had been published on an identical population, the studies with the longest follow-up period or the largest number of cases or the most recent publication date were selected. As a result, a total of 160 relevant studies including 148 occupational and 12 environmental exposure studies were identified. A flowchart of the selection process is provided in Fig. 1 .
Meta-analytic techniques that weight the logarithm of the RR of each study by a function of its variance were used to calculate a summary estimate. Due to a priori concerns regarding heterogeneity in the study populations, we used random-effects models for calculating summary statistics 8) . Differing asbestos exposure levels were combined into ever exposure through meta-analysis of categories of individual studies. These analyses were performed both on the total data set and separately for study characteristics including country of study, design, size, year of publication, gender, and exposure type (i.e., occupational, environmental). All statistical computations were performed using the STATA software version 11.0 (Statacorp., College Station, TX).
Calculation of hypothetical population attributable fraction
The potential attributable fraction was calculated through the following equation 9) in which PAF denotes the population attributable fraction and where P (E) is the proportion of the population exposed to asbestos and RR is the relative risk a lung cancer arising an exposed individual compared with those who are unexposed.
The meta-RRs from this study and hypothetical asbestos exposure prevalence ranging from 0% to 50% were ap- 
Results
The summary estimate from all studies showed a significant 1.8 fold-increased association for the relation between asbestos exposure and lung cancer ( Table 1 ). The risk of lung cancer due to asbestos exposure showed wide variation. Furthermore, risk estimates were higher in Asian countries (RR=3.53), in occupational exposure studies (RR=1.88), in papers published in the 1990s or earlier (RR=1.91), in studies with 500 or less subjects (RR=2.26) compared to those performed in Europe (RR=1.63) and North America (RR=1.49), in environmental exposure studies (RR=1.06), in studies published in the 2000s (RR=1.62), and in studies with 2000 more subjects (RR=1.51), respectively. The majority of studies were occupational retrospective cohort studies (n=112) and show relatively higher estimates than do case-control studies. The estimates did not meaningfully differ by gender and after adjusting for smoking. The European studies were conducted in the UK (n=19), Italy (n=19), Norway (n=10), Sweden (n=8), Finland (n=7), Australia (n=7), France (n=5), and others while the North American studies took place in the US (n=31) and Canada (n=5). Asian studies included China (n=23), Japan (n=7), and Israel (n=1) (data not shown).
Pooled results across regions are shown in Table 2 . The results of the meta-analysis by study characteristics presented consistently higher risks in Asian studies than in others, and the estimates from North America and Europe were generally similar. The results from Asian studies on males showed especially high RRs (RR=5.53, 95% CI 3.03-10.10) as did studies with 500 subjects or less (RR=5.48, 95% CI 3.44-8.73). However, the number of Asian studies was relatively small compared to those performed in Western countries.
The hypothetical PAFs were calculated using a range of scenarios of asbestos exposure prevalence and metaRRs from this study (Fig. 2) . The considerable variability in PAF estimates is mainly because of the high degree of variability by country. The PAFs for lung cancer grew with increasing exposure prevalence and the highest PAFs were found among Asian populations. The difference in PAFs between Asians and North Americans were 15.5%, 30.3%, and 36.2% when the exposure prevalence was 10%, 30%, and 50%, respectively. PAFs for lung cancer from asbestos exposure were also varied by exposure types, publication years, and population size (data not shown).
Discussion
Our findings demonstrated a potential difference in PAFs with different estimates on lung cancer and asbestos exposure. The biggest difference was observed in geographical area; therefore, the use of appropriate regionspecific risk estimates is necessary to obtain more exact PAFs. To our knowledge, this is the first study to evaluate the potential impact on the calculation of PAF for lung cancer associated with asbestos exposure using estimates of RRs derived through meta-analysis.
The extensive regional difference in lung cancer estimates implies that exposure to lung carcinogens varies greatly between nations. Possible reasons for the elevated 11) .
In addition, the types and sizes of asbestos exposure may different by countries. Differences in exposure between countries may arise from divergent legislation, technology, culture and attitude toward risk. Industrial Health 2013, 51, 128-133
A synergistic effect between tobacco smoke and asbestos in the causation of lung cancer 12, 13) may also explain this result. The prevalence of male smokers has generally decreased in Europe during the last decade, whereas the smoking rate remains high in many Asian countries 14) .
Therefore, the risk of lung cancer due to asbestos exposure may increase in Asian populations due to a high smoking prevalence, even though exposure levels may be similar with other countries. Biological differences may also influence the relationship between asbestos exposure and lung cancer by population. Previous studies have shown that polymorphisms in glutathione S-transferase isoenzymes and microsomal epoxide hydrolase may affect the risk for asbestos-related diseases 15, 16) . PON1 polymorphism may also be an important risk factor for chronic diseases, including lung cancer, and is known to have a pronounced variability across different ethnic groups 17) . A combination of differences from exposure, smoking prevalence, and genotype may produce the wide variation in RRs and corresponding PAFs in this study. Therefore, relative risk measured in one country under particular circumstances or a simple summary RR may not be applicable to a specific population in a different country. We also found different relative risks for lung cancer by publication year of studies, which may correlate with years of exposure to asbestos. Asbestos exposure may vary over time due to changing usage, control measures, and working practices and has probably decreased over time due to general improvements in technology 18) . Our results showed that the lung cancer risks in studies published in the 1990s or earlier were higher than those from the 2000s or later in all countries; therefore, differences in exposure over time are also of interest in assessing the occupational PAFs for lung cancer even within the same country. No significant association was observed between lung cancer and environmental asbestos exposure, whereas occupational exposure showed a significantly increased risk. The levels of environmental exposure to asbestos are generally low, and the duration and frequency of exposure are seldom precisely discernable with environmental exposure 19, 20) . Therefore, a high degree of heterogeneity may exist between studies of environmental exposure to asbestos. The reason for relatively high RRs in few-subject studies may relate to different exposure levels. Relatively smaller-scale industries may have higher exposure due to poor working conditions. Therefore the lung cancer risk in small studies can be higher than in larger studies. Unstable results due to small sample size offer another possible explanation since smaller studies tend more to induce bias away from null than do larger studies 21) .
Other differences in study design, asbestos types, subject selection, exposure patterns, diagnostic criteria, potential confounding factors and statistical techniques may explain the observed heterogeneity of risk estimates. Additionally, occupational cohort studies may vary greatly by industry, asbestos fiber type, and the demographic characteristics of cohort members 3) .
There are certain important limitations to this study. First, considerable heterogeneity may be present in the exposure assessment methods in the studies. Considering that the majority of studies are based on job exposure matrix or expert assessment, exposure information in this study may be inconsistent and there may be a degree of non-differential exposure misclassification. Second, we did not assess the methodological quality of the studies and hence did not exclude studies on the basis of quality score. Instead, we performed subgroup analyses according to study feature that could potentially affect the heterogeneity of individual studies.
Despite such limitations, we have conducted metaanalysis to evaluate the most up to date available RRs between lung cancer and asbestos exposure. These results demonstrated that the risks for lung cancer from asbestos exposure are variable according to the area under study, exposure type, population size, and year of publication. Our study differs from earlier reviews in that we have applied meta-results to the calculation of PAFs for lung cancer from asbestos exposure. Asian studies had the highest risk estimates and correspondingly produced the highest PAF. PAFs for lung cancer from asbestos exposure varied with different risk estimates at the same exposure prevalence. Therefore, caution is required using a single estimate for PAF, and it is important to apply adequate lung cancer estimates for each study population when calculating PAF to estimate the most appropriate disease burden in a country.
